Supernus and Indivior merge to create scaled, CNS-focused entity - Pharmaceutical Technology
Supernus Pharmaceuticals and Indivior are planning an all-stock merger to form a CNS-focused biopharma. The deal is expected to produce pro forma net revenue of $2.2bn and about $125m in annual cost synergies. Supernus brings Qelbree and Gocovri; Indivior brings Sublocade, Suboxone and Opvee. If completed in Q4 2026, the combined firm will trade as SUPN on Nasdaq.
How this was made
The 30-second read
Why it matters
The disclosed pro forma revenue ($2.2bn), expected annual cost synergies (~$125m), and planned Q4 2026 closing create a tradable catalyst for both companies, with valuation and risk hinging on deal terms and regulatory approval.
Market read
This is a primary M&A disclosure with quantified financial expectations (pro forma revenue and cost synergies) and a stated closing window, making it relevant for deal-spread and merger-arb positioning.
What to watch
The article omits key deal mechanics (exchange ratio, termination fees, regulatory hurdles). Those can dominate near-term pricing more than the headline synergy figure.
Background
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger to form a scaled, diversified CNS-focused biopharmaceutical company.
Ticker impact
Supernus and Indivior announced an all-stock merger expected to close in Q4 2026, with SUPN trading under the Supernus Inc name and SUPN ticker.
Likely positive near-term bias on deal spread tightening, with volatility around regulatory/closing risk.
The article provides concrete merger structure (all-stock), pro forma revenue ($2.2bn), and expected annual cost synergies (~$125m), plus leadership continuity for the combined entity.
Indivior is the other party in the proposed all-stock merger with Supernus, contributing its OUD portfolio and expected cost synergies.
Directionally positive if investors view the transaction as value-accretive, but with meaningful closing and integration uncertainty.
The text discloses merger expectations (Q4 2026 close), pro forma revenue ($2.2bn), and synergy target (~$125m), but provides no exchange ratio or definitive valuation mechanics.
Market effects
CNS and addiction-focused consolidation signal continued M&A appetite in neuropsychiatry and OUD franchises.
US-listed biopharma M&A narrative may support sentiment across small-to-mid cap CNS peers.
Highlights ongoing global dealmaking momentum, potentially influencing European and UK biopharma M&A expectations.
Counterpoint
Synergy targets and pro forma revenue may not translate into realized earnings power, especially if integration disrupts commercial execution in CNS and OUD.
Key entities
- companySupernus Pharmaceuticals
US biopharma company with CNS and neurology products including Qelbree and Gocovri.
- companyIndivior Pharmaceuticals
OUD-focused biopharma company with products including Sublocade, Suboxone, and Opvee.
- executiveJack Khattar
Supernus founder, CEO, and president expected to lead the combined entity as CEO.
- executiveTony Kingsley
Indivior non-executive director expected to serve as chair of the combined board.
